NHS treatment decision

• Health & Medicine

New treatment option made available for advanced womb cancers

Dostarlimab (also called Jemperli) has been recommended by the National Institute of Health and Care Excellence (NICE) to treat some types of advanced or recurrent womb cancer Dostarlimab (also called Jemperli) has been recommended by the National Institute of Health and Care Excellence (NICE) to treat some types of advanced or recurrent womb cancer

8 March 2024

• Health & Medicine

NHS offers first drug targeting advanced breast cancers driven by BRCA gene mutations

Around 300 people in England can receive talazoparib, which can stop advanced breast cancers with BRCA gene mutations growing for longer. Around 300 people in England can receive talazoparib, which can stop advanced breast cancers with BRCA gene mutations growing for longer.

25 January 2024

• Health & Medicine

New breast and lung cancer treatments approved in Scotland

3 new cancer treatments have now been approved by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland, including 2 breast cancer treatments and 1 for lung cancer. 3 new cancer treatments have now been approved by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland, including 2 breast cancer treatments and 1 for lung cancer.

19 January 2022

• Health & Medicine

New lung cancer treatment combo approved on NHS in England

A new treatment for some people with a type of non small cell lung cancer (NSCLC) will now be routinely available on the NHS in England, following its approval by the National Institute of Health and Care Excellence (NICE). A new treatment for some people with a type of non small cell lung cancer (NSCLC) will now be routinely available on the NHS in England, following its approval by the National Institute of Health and Care Excellence (NICE).

12 January 2022

• Health & Medicine

Immunotherapy approved for some people with advanced melanoma in England

The National Institute for Health and Care Excellence has recommended the use of the immunotherapy drug pembrolizumab (Keytruda) for some adults in England with a type of advanced melanoma skin cancer. The National Institute for Health and Care Excellence has recommended the use of the immunotherapy drug pembrolizumab (Keytruda) for some adults in England with a type of advanced melanoma skin cancer.

21 December 2021

• Health & Medicine

Ovarian, bowel and non-Hodgkin's lymphoma treatments approved for NHS use in Scotland

Three new treatment options made available for cancer patients in Scotland. Three new treatment options made available for cancer patients in Scotland.

16 December 2021

• Health & Medicine

Over 600 people in England set to benefit from innovative lung cancer treatment

More than 600 people in England with a form of lung cancer could benefit from the innovative drug osimertinib (Tagrisso) after its approval by the National Institute for Health and Care Excellence. More than 600 people in England with a form of lung cancer could benefit from the innovative drug osimertinib (Tagrisso) after its approval by the National Institute for Health and Care Excellence.

1 December 2021

• Health & Medicine

Targeted drug recommended to treat some advanced lung cancer patients

Selpercatinib will expand treatment options available for people with RET fusion positive non small cell lung cancer on the NHS in England. Selpercatinib will expand treatment options available for people with RET fusion positive non small cell lung cancer on the NHS in England.

25 November 2021

• Health & Medicine

Three cancer drugs approved for NHS use in Scotland

Three new cancer drugs have been given the go-ahead by the Scottish Medicines Consortium (SMC) for routine use in Scotland, two for non small cell lung cancer and one for Hodgkin lymphoma, but a fourth has been rejected. Three new cancer drugs have been given the go-ahead by the Scottish Medicines Consortium (SMC) for routine use in Scotland, two for non small cell lung cancer and one for Hodgkin lymphoma, but a fourth has been rejected.

11 November 2021

• Health & Medicine

Immunotherapy approved for some people with oesophageal cancer on NHS in England

The immunotherapy drug nivolumab (Opdivo) has been made available for some people in England with oesophageal cancer, in what has been described as a ‘step change’ for people with this cancer. The immunotherapy drug nivolumab (Opdivo) has been made available for some people in England with oesophageal cancer, in what has been described as a ‘step change’ for people with this cancer.

20 October 2021

• Health & Medicine

First targeted treatment approved for advanced prostate cancer on NHS in Scotland

The targeted drug olaparib has been approved for some people with a type of advanced prostate cancer on the NHS in Scotland. The targeted drug olaparib has been approved for some people with a type of advanced prostate cancer on the NHS in Scotland.

13 October 2021

• Health & Medicine

New drug available for rare thyroid cancer on NHS in England

The National Institute for Health and Care Excellence (NICE) has recommended the use of the drug selpercatinib (Retevmo) for some people in England with a type of advanced thyroid cancer. The National Institute for Health and Care Excellence (NICE) has recommended the use of the drug selpercatinib (Retevmo) for some people in England with a type of advanced thyroid cancer.

1 October 2021